GlassScriptPhysician profile
Renee Burkham
NPI 1235550401
$1,540.39
in general payments reported to CMS, 2019-2025
22 companies · $386 in 2025
The $386 reported for 2025 was more than what 81% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.19 · 2022: $365 · 2023: $414 · 2024: $357 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $237.42 | 2021-2025 | Nexplanon |
| Astellas Pharma US INC | $174.14 | 2023-2025 | Veozah, Vyloy |
| Hologic Sales and Service, LLC | $173.54 | 2023-2025 | Myosure Tissue Removal Device, Acessa Provu System, Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $132.12 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $113.98 | 2023-2025 | |
| Daiichi Sankyo INC. | $109.82 | 2022 | |
| Abbvie INC. | $96.78 | 2022 | |
| Biogen, INC. | $81.55 | 2024 | Zurzuvae |
| Dexcom, INC. | $70.03 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $62.26 | 2024-2025 | |
| Edwards Lifesciences Corporation | $43.90 | 2025 | Evoque |
| Merck Sharp & Dohme LLC | $39.83 | 2022-2023 | Gardasil 9 |
| Millicent US INC | $35.72 | 2023-2024 | Femring, Intrarosa |
| Exact Sciences Corporation | $23.18 | 2025 | Cologuard Collection Kit |
| Gynesonics, INC. | $22.34 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $21.00 | 2023 | Seglentis |
| Therapeuticsmd, INC. | $19.91 | 2022 | |
| Boston Scientific Corporation | $18.56 | 2025 | General - Pain Management |
| Aspira Women'S Health INC | $18.07 | 2024 | Ova1 |
| Shield Therapeutics INC | $16.62 | 2023 | |
| Sumitomo Pharma America, INC. | $15.50 | 2024 | Myfembree |
| Solventum Corporation | $14.12 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Burkham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.